Clinical haemophilia Long-term safety and efficacy of recombinant factor VIII Fc fusion protein ( rFVIIIFc ) in subjects with haemophilia

B. NOLAN,* J . MAHLANGU,† D. PERRY,‡ G. YOUNG,§ R. LIESNER,¶ B. KONKLE,** S. RANGARAJAN,†† S. BROWN,‡‡ H. HANABUSA,§§ K. J . PASI ,¶¶ I . PABINGER,*** S. JACKSON,††† L. M. CRISTIANO,‡‡‡ X. LI ,‡‡‡ G. F. PIERCE‡‡‡ and G. ALLEN‡‡‡ *Our Lady’s Children’s Hospital, Dublin, Ireland; †University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa; ‡Addenbrookes Hospital, Cambridge, UK; §Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; ¶Great Ormond Street Hospital, London, UK; **Puget Sound Blood Center, Seattle, WA, USA; ††Basingstoke and North Hampshire Hospital, Basingstoke, UK; ‡‡Lady Cilento Children’s Hospital, Brisbane, Qld, Australia; §§Ogikubo Hospital, Tokyo, Japan; ¶¶Barts and the London Comprehensive Care Center, London, UK; ***Medizinsche Universitat Wien, Vienna, Austria; †††St Paul’s Hospital, Vancouver, BC, Canada; and ‡‡‡Biogen, Cambridge, MA, USA